Lee CH, Wu SB, Hong CH, Yu HS, Wei YH. Molecular mechanisms of UV-induced apoptosis and its effects on skin residential cells: the implication in UV-based phototherapy. Int J Mol Sci. 2013;14(3):6414–35.
Edelson R, Berger C, Gasparro F, et al. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy preliminary results. N Engl J Med. 1987;316(6):297–303.
Decision Memo for Extracorporeal Photopheresis (ECP) (CAG-00324R2). https://http://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=255. Accessed 23 Jan 2017.
Couriel DR, Hosing C, Saliba R, et al. Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD. Blood. 2006;107(8):3074–80.
Neustadter JH, Samarin F, Carlson KR, Girardi M. Extracorporeal photochemotherapy for generalized deep morphea. Arch Dermatol. Feb 2009;145(2):127–30.
Pileri A, Raone B, Raboni R, Giudice V, Patrizi A. Generalized morphea successfully treated with extracorporeal photochemotherapy (ECP). Dermatol Online J. 2014;20(1):21258.
Schlaak M, Friedlein H, Kauer F, Renner R, Rogalski C, Simon JC. Successful therapy of a patient with therapy recalcitrant generalized bullous scleroderma by extracorporeal photopheresis and mycophenolate mofetil. J Eur Acad Dermatol Venereol. 2008;22(5):631–3.
Pileri A, Odorici G, Giudice V, Patrizi A, Bardazzi F. Bosentan and extracorporeal photochemotherapy in eosinophilic fasciitis: synergistic action or fortuitous coincidence? Int J Low Extrem Wounds. 2014;13(2):160–1.
Romano C, Rubegni P, De Aloe G, et al. Extracorporeal photochemotherapy in the treatment of eosinophilic fasciitis. J Eur Acad Dermatol Venereol. 2003;17(1):10–3.
Di Spaltro FX, Cottrill C, Cahill C, et al. Extracorporeal photochemotherapy in progressive systemic sclerosis. Int J Dermatol. 1993;32(6):417–21.
Fimiani M, Rubegni P, Flori ML, Mazzatenta C, D'Ascenzo G, Andreassi L. Three cases of progressive systemic sclerosis treated with extracorporeal photochemotherapy. Arch Dermatol Res. 1997;289(2):120–2.
• Knobler R, Berlin G, Calzavara-Pinton P, et al. Guidelines on the use of extracorporeal photopheresis. J Eur Acad Dermatol Venereol. 2014;28(Suppl 1):1–37. This article provides the most comprehensive available expert recommendations from the European Dermatology Forum on the use of extracorporeal photopheresis based on published literature and expert consensus opinion
Krasagakis K, Dippel E, Ramaker J, Owsianowski M, Orfanos CE. Management of severe scleroderma with long-term extracorporeal photopheresis. Dermatology. 1998;196(3):309–15.
Papp G, Horvath IF, Barath S, et al. Immunomodulatory effects of extracorporeal photochemotherapy in systemic sclerosis. Clin Immunol. Feb 2012;142(2):150–9.
Reich S, Gambichler T, Altmeyer P, Kreuter A. Extracorporeal photopheresis in systemic sclerosis: effects on organ involvement? J Am Acad Dermatol. Feb 2007;56(2):348–9.
Rook AH, Freundlich B, Jegasothy BV, et al. Treatment of systemic sclerosis with extracorporeal photochemotherapy. Results of a multicenter trial. Arch Dermatol. Mar 1992;128(3):337–46.
Liszewski W, Omland SH, Gniadecki R. The successful use of extracorporeal photopheresis in a 12-year-old patient with refractory epidermolysis bullosa acquisita. Pediatr Dermatol. 2015;32(2):e60–1.
Elewa R, Altenburg A, Zouboulis CC. Recalcitrant severe erosive cutaneous lichen planus treated with extracorporeal photopheresis monotherapy. Br J Dermatol. 2011;165(2):441–3.
Gollnick HP, Owsianowski M, Taube KM, Orfanos CE. Unresponsive severe generalized pemphigus vulgaris successfully controlled by extracorporeal photopheresis. J Am Acad Dermatol. 1993;28(1):122–4.
Liang G, Nahass G, Kerdel FA. Pemphigus vulgaris treated with photopheresis. J Am Acad Dermatol. 1992;26(5 Pt 1):779–80.
Rook AH. Photopheresis in the treatment of autoimmune disease: experience with pemphigus vulgaris and systemic sclerosis. Ann N Y Acad Sci. 1991;636:209–16.
Vonderheid EC, Kang CA, Kadin M, Bigler RD, Griffin TD, Rogers TJ. Extracorporeal photopheresis in psoriasis vulgaris: clinical and immunologic observations. J Am Acad Dermatol. 1990;23(4 Pt 1):703–12.
Vonderheid EC, Bigler RD, Rogers TJ, Kadin ME, Griffin TD. Effect of extracorporeal photopheresis on selected immunologic parameters in psoriasis vulgaris. Yale J Biol Med. 1989;62(6):653–64.
Akay BN, Sanli H, Kutlay S. Treatment of ankylosing spondylitis by extracorporeal photochemotherapy given for mycosis fungoides: a potential treatment option? J Clin Rheumatol. 2011;17(5):278–80.
Malawista SE, Trock DH, Edelson RL. Treatment of rheumatoid arthritis by extracorporeal photochemotherapy. A pilot study. Arthritis Rheum. 1991;34(6):646–54.
Berkson M, Lazarus GS, Uberti-Benz M, Rook AH. Extracorporeal photochemotherapy: a potentially useful treatment for scleromyxedema. J Am Acad Dermatol. 1991;25(4):724.
Knobler RM, Graninger W, Lindmaier A, Trautinger F. Photopheresis for the treatment of lupus erythematosus. Preliminary observations. Ann N Y Acad Sci. 1991;636:340–56.
Koppelhus U, Poulsen J, Grunnet N, Deleuran MS, Obitz E. Cyclosporine and extracorporeal photopheresis are equipotent in treating severe atopic dermatitis: a randomized cross-over study comparing two efficient treatment modalities. Front Med (Lausanne). 2014;1:33.
Radenhausen M, Michelsen S, Plewig G, Bechara FG, Altmeyer P, Hoffmann K. Bicentre experience in the treatment of severe generalised atopic dermatitis with extracorporeal photochemotherapy. J Dermatol. 2004;31(12):961–70.
Cavaletti G, Perseghin P, Dassi M, et al. Extracorporeal photochemotherapy: a safety and tolerability pilot study with preliminary efficacy results in refractory relapsing-remitting multiple sclerosis. Neurol Sci. 2006;27(1):24–32.
Besnier DP, Chabannes D, Mussini JM, Dupas B, Esnault VL. Extracorporeal photochemotherapy for secondary chronic progressive multiple sclerosis: a pilot study. Photodermatol Photoimmunol Photomed. 2002;18(1):36–41.
Rostami AM, Sater RA, Bird SJ, et al. A double-blind, placebo-controlled trial of extracorporeal photopheresis in chronic progressive multiple sclerosis. Mult Scler. 1999;5(3):198–203.
Fowler S, Jones J, Hull PR, Ghosh S. Extracorporeal photopheresis for the treatment of Crohn’s disease. Transfus Apher Sci. 2015;52(2):183–6.
Cheerva A, Dillard R, Bertolone S. Extracorporeal photopheresis for the treatment of severe, refractory steroid dependent pediatric Crohn’s disease. J Clin Apher. 2013;28(5):381–6.
Reinisch W, Knobler R, Rutgeerts PJ, et al. Extracorporeal photopheresis (ECP) in patients with steroid-dependent Crohn’s disease: an open-label, multicenter, prospective trial. Inflamm Bowel Dis. 2013;19(2):293–300.
Abreu MT, von Tirpitz C, Hardi R, et al. Extracorporeal photopheresis for the treatment of refractory Crohn’s disease: results of an open-label pilot study. Inflamm Bowel Dis. 2009;15(6):829–36.
Ludvigsson J, Samuelsson U, Ernerudh J, Johansson C, Stenhammar L, Berlin G. Photopheresis at onset of type 1 diabetes: a randomised, double blind, placebo controlled trial. Arch Dis Child. 2001;85(2):149–54.
Find an ECP Treatment Center in the United States and Canada. http://www.therakos.com/treatment-center-locator. Accessed January 23, 2017.
Therakos Photopheresis Immunotherapy. http://www.therakos.com/therakos-photopheresis-immunotherapy. Accessed 23 Jan 2017.
Sokhn JG, Choi J, Foss FM. Photopheresis. In: Wingard JR, Gastineau DA, Leather HL, Snyder EL, Szczepiorkowski ZM, eds. Hematopoietic stem cell transplantation: a handbook for clinicians. 2nd edition. ed. Bethesda, MD: AABB; 2014.
UVADEX. Full Prescribing Information. http://www.therakos.co.uk/full-prescribing-information. Accessed January 24, 2017.
"THERAKOS® CELLEX® Photopheresis System: Operator's Manual". Technical Bulletin #18 Rev B: 1460033_EN-US ed: Therakos, Inc; 2014.
Klassen J. The role of photopheresis in the treatment of graft-versus-host disease. Curr Oncol. 2010;17(2):55–8.
Rangarajan HG, Punzalan RC, Camitta BM, Talano JA. The use of novel Therakos Cellex(R) for extracorporeal photopheresis in treatment of graft-versus-host disease in paediatric patients. Br J Haematol. 2013;163(3):357–64.
Wolff D, Schleuning M, von Harsdorf S, et al. Consensus conference on clinical practice in chronic GVHD: second-line treatment of chronic graft-versus-host disease. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2011;17(1):1–17.
Matsumura Y, Ananthaswamy HN. Short-term and long-term cellular and molecular events following UV irradiation of skin: implications for molecular medicine. Expert Rev Mol Med. 2002;4(26):1–22.
Knobler RM, Trautinger F, Graninger W, et al. Parenteral administration of 8-methoxypsoralen in photopheresis. J Am Acad Dermatol. 1993;28(4):580–4.
Hart JW, Shiue LH, Shpall EJ, Alousi AM. Extracorporeal photopheresis in the treatment of graft-versus-host disease: evidence and opinion. Therapeutic advances in hematology. 2013;4(5):320–34.
Schneiderman J, Jacobsohn DA, Collins J, Thormann K, Kletzel M. The use of fluid boluses to safely perform extracorporeal photopheresis (ECP) in low-weight children: a novel procedure. J Clin Apher. 2010;25(2):63–9.
Uygun V, Daloglu H, Karasu G, Hazar V, Yesilipek A. Safety and outcomes of extracorporeal photopheresis with the Therakos Cellex System for graft-versus-host disease in pediatric patients. J Pediatr Hematol Oncol. Apr 2015;37(3):209–14.
Berger C, Hoffmann K, Vasquez JG, et al. Rapid generation of maturationally synchronized human dendritic cells: contribution to the clinical efficacy of extracorporeal photochemotherapy. Blood. 2010;116(23):4838–47.
• Edelson RL. Mechanistic insights into extracorporeal photochemotherapy: efficient induction of monocyte-to-dendritic cell maturation. Transfus Apher Sci. 2014;50(3):322–9. This article provides mechanistic insights from one of the founding fathers of ECP, who discusses ECP’s generation of dendritic cells and its immunomodulatory effects
Choi J, Heald PW, Girardi M. Extracorporeal photochemotherapy (photopheresis). In: Wolverton SE, ed. Comprehensive dermatologic drug therapy. 3rd ed 2012:291–298.
Lemke G, Rothlin CV. Immunobiology of the TAM receptors. Nat Rev Immunol. 2008;8(5):327–36.
Lemke G, Burstyn-Cohen T. TAM receptors and the clearance of apoptotic cells. Ann N Y Acad Sci. 2010;1209:23–9.
Xia CQ, Campbell KA, Clare-Salzler MJ. Extracorporeal photopheresis-induced immune tolerance: a focus on modulation of antigen-presenting cells and induction of regulatory T cells by apoptotic cells. Curr Opin Organ Transplant. 2009;14(4):338–43.
• Li H, Shi B. Tolerogenic dendritic cells and their applications in transplantation. Cellular & molecular immunology. 2015;12(1):24–30. This article discusses current knowledge of tolerogenic dendritic cells and their immune effects
Capitini CM, Davis JP, Larabee SM, Herby S, Nasholm NM, Fry TJ. Extracorporeal photopheresis attenuates murine graft-versus-host disease via bone marrow-derived interleukin-10 and preserves responses to dendritic cell vaccination. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2011;17(6):790–9.
Morelli AE, Thomson AW. Tolerogenic dendritic cells and the quest for transplant tolerance. Nat Rev Immunol. 2007;7(8):610–21.
Biagi E, Di Biaso I, Leoni V, et al. Extracorporeal photochemotherapy is accompanied by increasing levels of circulating CD4+CD25+GITR+Foxp3+CD62L+ functional regulatory T-cells in patients with graft-versus-host disease. Transplantation. 2007;84(1):31–9.
Gatza E, Rogers CE, Clouthier SG, et al. Extracorporeal photopheresis reverses experimental graft-versus-host disease through regulatory T cells. Blood. 2008;112(4):1515–21.
Maeda A, Schwarz A, Bullinger A, Morita A, Peritt D, Schwarz T. Experimental extracorporeal photopheresis inhibits the sensitization and effector phases of contact hypersensitivity via two mechanisms: generation of IL-10 and induction of regulatory T cells. J Immunol. 2008;181(9):5956–62.
Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 1995;155(3):1151–64.
Sojka DK, Huang YH, Fowell DJ. Mechanisms of regulatory T-cell suppression–a diverse arsenal for a moving target. Immunology. 2008;124(1):13–22.
Maeda A, Schwarz A, Kernebeck K, et al. Intravenous infusion of syngeneic apoptotic cells by photopheresis induces antigen-specific regulatory T cells. J Immunol. 2005;174(10):5968–76.
George JF, Gooden CW, Guo L, Kirklin JK. Role for CD4(+)CD25(+) T cells in inhibition of graft rejection by extracorporeal photopheresis. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation. 2008;27(6):616–22.
Meloni F, Cascina A, Miserere S, Perotti C, Vitulo P, Fietta AM. Peripheral CD4(+)CD25(+) TREG cell counts and the response to extracorporeal photopheresis in lung transplant recipients. Transplant Proc. 2007;39(1):213–7.
Lamioni A, Carsetti R, Legato A, et al. Induction of regulatory T cells after prophylactic treatment with photopheresis in renal transplant recipients. Transplantation. 2007;83(10):1393–6.
Denney HA, Whittle RJ, Lai J, Jacques RM, Taylor PC. Regulatory T cells in chronic graft-versus-host disease after extracorporeal photopheresis: correlation with skin and global organ responses, and ability to taper steroids. Transplantation. 2017;101(1):204–11.
Ward DM. Extracorporeal photopheresis: how, when, and why. J Clin Apher. 2011;26(5):276–85.
O'Reilly S, Hugle T, van Laar JM. T cells in systemic sclerosis: a reappraisal. Rheumatology (Oxford). 2012;51(9):1540–9.
Papp G, Horvath IF, Barath S, et al. Altered T-cell and regulatory cell repertoire in patients with diffuse cutaneous systemic sclerosis. Scand J Rheumatol. 2011;40(3):205–10.
Radstake TR, van Bon L, Broen J, et al. The pronounced Th17 profile in systemic sclerosis (SSc) together with intracellular expression of TGFbeta and IFNgamma distinguishes SSc phenotypes. PLoS One. 2009;4(6):e5903.
• Yang X, Yang J, Xing X, Wan L, Li M. Increased frequency of Th17 cells in systemic sclerosis is related to disease activity and collagen overproduction. Arthritis Res Ther. 2014;16(1):R4. This study provides evidence that Th17 is involved in the pathogenesis of systemic sclerosis
• Slobodin G, Rimar D. Regulatory T Cells in Systemic Sclerosis: a Comprehensive Review. Clin Rev Allergy Immunol. 2016. This article discusses the controversial role of regulatory T cells in systemic sclerosis.
Liu X, Gao N, Li M, et al. Elevated levels of CD4(+)CD25(+)FoxP3(+) T cells in systemic sclerosis patients contribute to the secretion of IL-17 and immunosuppression dysfunction. PLoS One. 2013;8(6):e64531.
Slobodin G, Ahmad MS, Rosner I, et al. Regulatory T cells (CD4(+)CD25(bright)FoxP3(+)) expansion in systemic sclerosis correlates with disease activity and severity. Cell Immunol. 2010;261(2):77–80.
Jiang N, Li M, Zeng X. Correlation of Th17 cells and CD4(+)CD25(+) regulatory T cells with clinical parameters in patients with systemic sclerosis. Chin Med J. 2014;127(20):3557–61.
Klein S, Kretz CC, Ruland V, et al. Reduction of regulatory T cells in skin lesions but not in peripheral blood of patients with systemic scleroderma. Ann Rheum Dis. 2011;70(8):1475–81.
Antiga E, Quaglino P, Bellandi S, et al. Regulatory T cells in the skin lesions and blood of patients with systemic sclerosis and morphoea. Br J Dermatol. 2010;162(5):1056–63.
Fenoglio D, Battaglia F, Parodi A, et al. Alteration of Th17 and Treg cell subpopulations co-exist in patients affected with systemic sclerosis. Clin Immunol. 2011;139(3):249–57.
Ferri C, Valentini G, Cozzi F, et al. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore). 2002;81(2):139–53.
Scussel-Lonzetti L, Joyal F, Raynauld JP, et al. Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. Medicine (Baltimore). 2002;81(2):154–67.
Cribier B, Faradji T, Le Coz C, Oberling F, Grosshans E. Extracorporeal photochemotherapy in systemic sclerosis and severe morphea. Dermatology. 1995;191(1):25–31.
Enomoto DN, Mekkes JR, Bossuyt PM, et al. Treatment of patients with systemic sclerosis with extracorporeal photochemotherapy (photopheresis). J Am Acad Dermatol. 1999;41(6):915–22.
Knobler RM, French LE, Kim Y, et al. A randomized, double-blind, placebo-controlled trial of photopheresis in systemic sclerosis. J Am Acad Dermatol. 2006;54(5):793–9.
Muellegger RR, Hofer A, Salmhofer W, Soyer HP, Kerl H, Wolf P. Extended extracorporeal photochemotherapy with extracorporeal administration of 8-methoxypsoralen in systemic sclerosis. An Austrian single-center study. Photodermatol Photoimmunol Photomed. 2000;16(5):216–23.
Schwartz J, Winters JL, Padmanabhan A, et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the sixth special issue. J Clin Apher. Jul 2013;28(3):145–284.
Guideline on Extracoporeal Photopheresis. European Dermatology Forum; 2013. http://www.euroderm.org/edf/index.php/edf-guidelines/category/5-guidelines-miscellaneous?download=39:guideline-extracorporeal-photopheresis. Accessed 1 Mar 2017.